{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:48:36Z","timestamp":1773038916391,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.biomaterials.2022.121766","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T08:27:55Z","timestamp":1661934475000},"page":"121766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Rapamycin-encapsulated costimulatory ICOS\/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment"],"prefix":"10.1016","volume":"289","author":[{"given":"Jiali","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5875-4417","authenticated-orcid":false,"given":"Nan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3781-7845","authenticated-orcid":false,"given":"Yourong","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biomaterials.2022.121766_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121766_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","article-title":"New therapeutic strategies in systemic lupus erythematosus management","volume":"15","author":"Gatto","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121766_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41584-019-0235-5","article-title":"New therapies for systemic lupus erythematosus - past imperfect, future tense","volume":"15","author":"Murphy","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121766_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.molmed.2020.09.009","article-title":"Leveraging heterogeneity in systemic lupus erythematosus for new therapies","volume":"27","author":"Allen","year":"2021","journal-title":"Trends Mol. Med."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121766_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nri3447","article-title":"The good, the bad and the ugly - TFH cells in human health and disease","volume":"13","author":"Tangye","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121766_bib6","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann. Intern. Med."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121766_bib7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/s41573-020-0081-9","article-title":"Targeting co-stimulatory molecules in autoimmune disease","volume":"19","author":"Edner","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2022.121766_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121766_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/imr.12747","article-title":"TFH cells in bystander and cognate interactions with B cells","volume":"288","author":"Wan","year":"2019","journal-title":"Immunol. Rev."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121766_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2567.2008.02991.x","article-title":"CD28 and inducible costimulator (ICOS) signalling can sustain CD154 expression on activated T cells","volume":"127","author":"Kaminski","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.biomaterials.2022.121766_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104420","article-title":"Distinct roles of ICOS and CD40L in human T-B cell adhesion and antibody production","volume":"368","author":"Liu","year":"2021","journal-title":"Cell. Immunol."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121766_bib12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/89731","article-title":"Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection","volume":"2","author":"Ozkaynak","year":"2001","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121766_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.TP.0000165429.57421.D6","article-title":"Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade","volume":"80","author":"Guillonneau","year":"2005","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121766_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41584-019-0356-x","article-title":"T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy","volume":"16","author":"Sharabi","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121766_bib15","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.12847","article-title":"Metabolic determinants of lupus pathogenesis","volume":"295","author":"Teng","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biomaterials.2022.121766_bib16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/annrheumdis-2021-221464","article-title":"Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus","volume":"81","author":"Takeshima","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121766_bib17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.it.2018.04.006","article-title":"Metabolism as a target for modulation in autoimmune diseases","volume":"39","author":"Huang","year":"2018","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121766_bib18","doi-asserted-by":"crossref","DOI":"10.20892\/j.issn.2095-3941.2019.0156","article-title":"Preparation, characterization, pharmacokinetics and anticancer effects of PEGylated \u03b2-elemene liposomes","volume":"17","author":"Zhai","year":"2020","journal-title":"Cancer Biology and Medicine"},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121766_bib19","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.addr.2012.03.006","article-title":"Development of macromolecular prodrug for rheumatoid arthritis","volume":"64","author":"Yuan","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121766_bib20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.20892\/j.issn.2095-3941.2020.0496","article-title":"Stimuli-responsive nanocarriers for therapeutic applications in cancer","volume":"18","author":"Zhao","year":"2021","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121766_bib21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-017-02251-3","article-title":"Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121766_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-017-02251-3","article-title":"Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121766_bib23","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1172\/JCI120923","article-title":"Targeted delivery of immune therapeutics to lymph nodes prolongs cardiac allograft survival","volume":"128","author":"Bahmani","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"7533","key":"10.1016\/j.biomaterials.2022.121766_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature13803","article-title":"T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction","volume":"517","author":"Liu","year":"2015","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121766_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/cmi.2012.18","article-title":"The development and function of follicular helper T cells in immune responses","volume":"9","author":"Chen","year":"2012","journal-title":"Cell. Mol. Immunol."},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121766_bib26","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/eji.201040391","article-title":"IL-6: regulator of Treg\/Th17 balance","volume":"40","author":"Kimura","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121766_bib27","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","article-title":"The spleen in local and systemic regulation of immunity","volume":"39","author":"Bronte","year":"2013","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.biomaterials.2022.121766_bib28","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1136\/annrheumdis-2013-203794","article-title":"HRES-1\/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE","volume":"73","author":"Caza","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biomaterials.2022.121766_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2021.108781","article-title":"Improvement of renal and non-renal SLE outcome measures on sirolimus therapy - a 21-year follow-up study of 73 patients","volume":"229","author":"Piranavan","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.biomaterials.2022.121766_bib30","series-title":"Renal mTORC1 Activation Is Associated with Disease Activity and Prognosis in Lupus Nephritis, Rheumatology (Oxford)","author":"Mao","year":"2022"},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121766_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/art.40380","article-title":"Blockade of Treg cell differentiation and function by the interleukin-21-mechanistic target of rapamycin Axis via suppression of autophagy in patients with systemic lupus erythematosus","volume":"70","author":"Kato","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121766_bib32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/art.1780370219","article-title":"Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus","volume":"37","author":"Warner","year":"1994","journal-title":"Arthritis Rheum."},{"issue":"12","key":"10.1016\/j.biomaterials.2022.121766_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102984","article-title":"Therapeutic mTOR blockade in systemic autoimmunity: implications for antiviral immunity and extension of lifespan","volume":"20","author":"Geier","year":"2021","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.biomaterials.2022.121766_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.biomaterials.2022.121766_bib35","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121766_bib36","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1172\/JCI78087","article-title":"T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity","volume":"125","author":"Moulton","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121766_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/eji.201545760","article-title":"T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis","volume":"46","author":"Blanco","year":"2016","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.biomaterials.2022.121766_bib38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrrheum.2016.158","article-title":"Beyond pan-B-cell-directed therapy - new avenues and insights into the pathogenesis of SLE","volume":"12","author":"Dorner","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.biomaterials.2022.121766_bib39","article-title":"The bm12 inducible model of systemic lupus erythematosus (SLE) in C57BL\/6 mice","volume":"105","author":"Klarquist","year":"2015","journal-title":"JoVE"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121766_bib40","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"Update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121766_bib41","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biomaterials.2022.121766_bib42","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/d41573-022-00040-2","article-title":"Bispecific antibodies in oncology","volume":"21","author":"Esfandiari","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7900","key":"10.1016\/j.biomaterials.2022.121766_bib43","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biomaterials.2022.121766_bib44","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.it.2018.04.006","article-title":"Metabolism as a target for modulation in autoimmune diseases","volume":"39","author":"Huang","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.biomaterials.2022.121766_bib45","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13075-015-0757-4","article-title":"CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study","volume":"17","author":"Shock","year":"2015","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121766_bib46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the 'high-hanging fruit","volume":"17","author":"Carter","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.biomaterials.2022.121766_bib47","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nnano.2017.69","article-title":"Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy","volume":"12","author":"Yuan","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"5","key":"10.1016\/j.biomaterials.2022.121766_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121766_bib49","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2006-01-010124","article-title":"Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)","volume":"108","author":"Teachey","year":"2006","journal-title":"Blood"},{"issue":"10126","key":"10.1016\/j.biomaterials.2022.121766_bib50","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/S0140-6736(18)30485-9","article-title":"Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1\/2 trial","volume":"391","author":"Lai","year":"2018","journal-title":"Lancet"},{"issue":"6816","key":"10.1016\/j.biomaterials.2022.121766_bib51","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35051113","article-title":"ICOS is essential for effective T-helper-cell responses","volume":"409","author":"Tafuri","year":"2001","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biomaterials.2022.121766_bib52","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.4049\/jimmunol.166.6.3659","article-title":"Cutting edge: critical role of inducible costimulator in germinal center reactions","volume":"166","author":"Dong","year":"2001","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121766_bib53","doi-asserted-by":"crossref","first-page":"491","DOI":"10.4049\/jimmunol.1502241","article-title":"Loss of immune tolerance is controlled by ICOS in Sle1 mice","volume":"197","author":"Mittereder","year":"2016","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121766_bib54","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23185","article-title":"ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells","volume":"2","author":"Faget","year":"2013","journal-title":"OncoImmunology"},{"issue":"20","key":"10.1016\/j.biomaterials.2022.121766_bib55","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1158\/0008-5472.CAN-12-2271","article-title":"Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells","volume":"72","author":"Conrad","year":"2012","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biomaterials.2022.121766_bib56","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4049\/jimmunol.2100897","article-title":"ICOS-deficient regulatory T cells can prevent spontaneous autoimmunity but are impaired in controlling acute inflammation","volume":"209","author":"Chang","year":"2022","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121766_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5114\/ceji.2021.109171","article-title":"The posttraumatic response of CD4+ regulatory T cells is modulated by direct cell-cell contact via CD40L- and P-selectin-dependent pathways","volume":"46","author":"Rupp","year":"2021","journal-title":"Cent. Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.biomaterials.2022.121766_bib58","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","article-title":"Treg cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat. Rev. Immunol."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222004069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961222004069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:14:31Z","timestamp":1758906871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961222004069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":58,"alternative-id":["S0142961222004069"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121766","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rapamycin-encapsulated costimulatory ICOS\/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121766"}}